Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Free Report) – Analysts at Zacks Research raised their FY2026 earnings per share (EPS) estimates for shares of Ironwood Pharmaceuticals in a note issued to investors on Thursday, August 27th. Zacks Research analyst Team now expects that the biotechnology company will post earnings of $1.10 per share for the year, up from their prior estimate of $1.04. Zacks Research has a “Hold” rating on the stock. The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $1.10 per share. Zacks Research also issued estimates for Ironwood Pharmaceuticals’ Q1 2028 earnings at $0.02 EPS and Q2 2028 earnings at $0.01 EPS.
Several other research firms have also recently weighed in on IRWD. Wall Street Zen raised Ironwood Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 22nd. Weiss Ratings raised Ironwood Pharmaceuticals from a “hold (c-)” rating to a “hold (c+)” rating in a report on Friday, August 21st. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $6.23.
Ironwood Pharmaceuticals Trading Up 2.9%
Shares of IRWD stock opened at $4.25 on Monday. Ironwood Pharmaceuticals has a 12-month low of $1.01 and a 12-month high of $5.78. The stock has a market capitalization of $702.27 million, a P/E ratio of 5.52 and a beta of 0.20. The firm’s 50 day moving average is $4.15 and its 200 day moving average is $3.89.
Ironwood Pharmaceuticals (NASDAQ:IRWD – Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $0.31 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.01). Ironwood Pharmaceuticals had a net margin of 33.36% and a negative return on equity of 58.38%. The company had revenue of $113.04 million for the quarter, compared to analysts’ expectations of $114.84 million.
Hedge Funds Weigh In On Ironwood Pharmaceuticals
Institutional investors have recently bought and sold shares of the stock. Dimensional Fund Advisors LP grew its holdings in Ironwood Pharmaceuticals by 529.3% during the first quarter. Dimensional Fund Advisors LP now owns 2,082,055 shares of the biotechnology company’s stock valued at $7,307,000 after purchasing an additional 1,751,219 shares during the period. Inspire Investing LLC bought a new position in shares of Ironwood Pharmaceuticals in the first quarter worth about $1,790,000. Pacer Advisors Inc. bought a new position in shares of Ironwood Pharmaceuticals in the first quarter worth about $3,982,000. Hillsdale Investment Management Inc. bought a new position in shares of Ironwood Pharmaceuticals in the fourth quarter worth about $3,897,000. Finally, Globeflex Capital L P purchased a new position in shares of Ironwood Pharmaceuticals during the 2nd quarter valued at about $1,094,000.
Insider Activity at Ironwood Pharmaceuticals
In other Ironwood Pharmaceuticals news, insider Ronald Silver sold 127,890 shares of the stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $4.52, for a total value of $578,062.80. Following the transaction, the insider directly owned 313,680 shares in the company, valued at approximately $1,417,833.60. This trade represents a 28.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Julie Mchugh sold 21,571 shares of Ironwood Pharmaceuticals stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $3.73, for a total transaction of $80,459.83. Following the transaction, the director owned 250,749 shares in the company, valued at $935,293.77. This represents a 7.92% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 9.30% of the company’s stock.
Ironwood Pharmaceuticals Company Profile
Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.
Read More
- Five stocks we like better than Ironwood Pharmaceuticals
- Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
- Insiders Are Betting Big on These 3 Healthcare Stocks
- 3 Stocks for Investors Who Still Believe Cash Is King
- Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
